Clinical Trials Logo

Chronic Myeloid Leukaemia clinical trials

View clinical trials related to Chronic Myeloid Leukaemia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01804985 Active, not recruiting - Clinical trials for Chronic Myeloid Leukaemia

De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia

DESTINY
Start date: December 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate whether some patients with excellent responses to chronic myeloid leukaemia (CML) treatment are being overtreated, and can remain well on either a lower dose of treatment or without treatment at all. The dose of imatinib (Glivec), nilotinib (Tasigna) or dasatinib (Sprycel) treatment will initially be cut to half the standard dose for 12 months, and then treatment will be stopped completely for a further two years. The trial information will also help to develop a de-escalation and stopping strategy for future newly diagnosed CML patients in the next British national CML study (to be known as SPIRIT3).

NCT ID: NCT01699217 Active, not recruiting - Clinical trials for Chronic Myeloid Leukaemia

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase

CML0912
Start date: June 21, 2013
Phase:
Study type: Observational

The GIMEMA CML Working Party promotes a multicentre, observational, prospective study of CML patients treated frontline with NIL. Patients will be followed for 5 years. This study will help the definition of guidelines for the treatment of CML patients in early CP.